European Equities Traded in the US as American Depositary Receipts Start Week Trending Higher in Monday Trading

MT Newswires Live
Yesterday

European equities traded in the US as American depositary receipts opened the week higher late Monday morning, rising 0.77% to 1,603.65 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical companies Cellectis (CLLS) and Genfit (GNFT), which climbed 12.2% and 7.2% respectively. They were followed by 3D printer company Materialise (MTLS) and lender Banco Bilbao Vizcaya Argentaria (BBVA), which advanced 4.8% and 2.4% respectively.

The decliners from continental Europe were led by petroleum refiner Equinor (EQNR) and telecommunications operator Telefonica (TEF), which fell 2.2% and 1.4% respectively. They were followed by consumer goods giant Unilever (UL) and telecommunications company Ericsson (ERIC), which were down 1% and 0.8% respectively.

From the UK and Ireland, the gainers were led by alcoholic beverage company Diageo (DEO) and biotech firm Autolus Therapeutics (AUTL), which rose 4.9% and 2.2% respectively. They were followed by pharmaceutical company AstraZeneca (AZN) and biopharmaceutical company Amarin (AMRN), which were up 1.6% and 0.9% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Akari Therapeutics (AKTX) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which dropped 6% and 4.4% respectively. They were followed by software firm Endava (DAVA) and pharmaceutical company Silence Therapeutics (SLN), which lost 3% and 1.2% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10